WallStSmart

Canopy Growth Corp (CGC)vsViatris Inc (VTRS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Viatris Inc generates 4919% more annual revenue ($14.74B vs $293.63M). VTRS leads profitability with a -2.8% profit margin vs -79.2%. VTRS earns a higher WallStSmart Score of 48/100 (D+).

CGC

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 2.0Value: 5.0Quality: 6.5
Piotroski: 4/9Altman Z: -12.96

VTRS

Hold

48

out of 100

Grade: D+

Growth: 2.7Profit: 3.5Value: 4.3Quality: 5.0
Piotroski: 4/9Altman Z: 0.55
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for CGC.

VTRSSignificantly Overvalued (-85.0%)

Margin of Safety

-85.0%

Fair Value

$8.72

Current Price

$16.51

$7.79 premium

UndervaluedFair: $8.72Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CGC1 strengths · Avg: 10.0/10
Price/BookValuation
0.8x10/10

Reasonable price relative to book value

VTRS1 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Areas to Watch

CGC4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$416.81M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-37.6%2/10

ROE of -37.6% — below average capital efficiency

Free Cash FlowQuality
$-25.75M2/10

Negative free cash flow — burning cash

VTRS4 concerns · Avg: 2.5/10
Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Return on EquityProfitability
-2.9%2/10

ROE of -2.9% — below average capital efficiency

EPS GrowthGrowth
-70.6%2/10

Earnings declined 70.6%

Altman Z-ScoreHealth
0.552/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : CGC

The strongest argument for CGC centers on Price/Book. Revenue growth of 12.5% demonstrates continued momentum.

Bull Case : VTRS

The strongest argument for VTRS centers on Price/Book. PEG of 1.05 suggests the stock is reasonably priced for its growth.

Bear Case : CGC

The primary concerns for CGC are EPS Growth, Market Cap, Return on Equity.

Bear Case : VTRS

The primary concerns for VTRS are Revenue Growth, Return on Equity, EPS Growth.

Key Dynamics to Monitor

CGC carries more volatility with a beta of 2.43 — expect wider price swings.

CGC is growing revenue faster at 12.5% — sustainability is the question.

VTRS generates stronger free cash flow (329M), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.

Bottom Line

VTRS scores higher overall (48/100 vs 36/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Canopy Growth Corp

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Canopy Growth Corporation is engaged in the production, distribution and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. The company is headquartered in Smiths Falls, Canada.

Viatris Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.

Visit Website →

Want to dig deeper into these stocks?